NCT04351919 (COVID+PA) is a Phase 4 clinical trial of Hydroxychloroquine in Patients With COVID19, sponsored by Abderrahmane Mami Hospital.

Who is sponsoring NCT04351919?

NCT04351919 is sponsored by Abderrahmane Mami Hospital.

What drugs are being tested in NCT04351919?

Interventions in NCT04351919: Hydroxychloroquine, Azithromycin.

What condition does NCT04351919 study?

NCT04351919 studies Patients With COVID19.

Is NCT04351919 still recruiting?

NCT04351919 is currently withdrawn. Last updated 28 August 2020.

Last reviewed 2020-08-28 · How we verify

NCT04351919: COVID+PA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+)

Withdrawn Phase 4 Last updated 28 August 2020

What this trial tests

Phase 4 trial testing Hydroxychloroquine in Patients With COVID19. Withdrawn.

Timeline

5 May 2020

Primary endpoint
15 July 2020

15 July 2020

Quick facts

Lead sponsor	Abderrahmane Mami Hospital
Phase	Phase 4
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	5 May 2020
Primary completion	15 July 2020
Estimated completion	15 July 2020
Sites	1 location across Tunisia

Drugs / interventions tested

Hydroxychloroquine (HYDROXYCHLOROQUINE) — full drug profile →
Azithromycin (azithromycin) — full drug profile →

Conditions studied

Patients With COVID19 — all drugs for Patients With COVID19 →

Sponsor

Abderrahmane Mami Hospital

Who can join

Adults 18 to 80, any sex, with Patients With COVID19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will assess the number of patients who become asymptomatic from clinical signs of COVID19 and will assess the efficacy of Hydroxychloroquine (HCQ) and Azithromycine effects on paucisymptomatic patients with ou without co-morbidities

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
Singh B, Ryan H, Kredo T, Chaplin M, et al · · 2021 · cited 140× · PMID 33624299 · DOI 10.1002/14651858.cd013587.pub2
Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.
Pani A, Lauriola M, Romandini A, Scaglione F. · · 2020 · cited 73× · PMID 32534189 · DOI 10.1016/j.ijantimicag.2020.106053
Widely available lysosome targeting agents should be considered as potential therapy for COVID-19.
Homolak J, Kodvanj I. · · 2020 · cited 54× · PMID 32522674 · DOI 10.1016/j.ijantimicag.2020.106044
Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines).
Slimano F, Baudouin A, Zerbit J, Toulemonde-Deldicque A, et al · · 2020 · cited 29× · PMID 32623296 · DOI 10.1016/j.ctrv.2020.102063
Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment.
Zou H, Yang Y, Dai H, Xiong Y, et al · · 2021 · cited 12× · PMID 34880750 · DOI 10.3389/fphar.2021.732403
Management of SARS-CoV-2 Infection: Key Focus in Macrolides Efficacy for COVID-19.
Batiha GE, Zayed MA, Awad AA, Shaheen HM, et al · · 2021 · cited 11× · PMID 33937285 · DOI 10.3389/fmed.2021.642313
SARS-Cov-2: Biology, Detection, Macrophage Mediated Pathogenesis and Potential Treatments.
Borges-Velez G, Rosario-Rodriguez LJ, Rosado-Philippi JE, Cartagena LJ, et al · · 2020 · cited 3× · PMID 34485853 · DOI 10.23880/vij-16000242

Verify or expand the search:

Other trials of Hydroxychloroquine

Trials testing the same drug.

NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07343635 — The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined · NA · recruiting
NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
NCT06971744 — Autophagy Maintenance (AUTOMAIN) · Phase 2 · recruiting
NCT05841758 — Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis · Phase 4 · recruiting

Other Abderrahmane Mami Hospital trials

Trials by the same sponsor.

NCT06392568 — Epidemiological Features of Emergent Highly Resistant Bacteria in Tunisian Intensive Care Units · recruiting
NCT05547646 — The Prevalence of Healthcare-associated Infection in Medical Intensive Care Units in Tunisia · completed
NCT04361032 — Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID · Phase 3 · unknown
NCT04528927 — Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Ac · Phase 3 · withdrawn
NCT04349228 — Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals · Phase 3 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04351919 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abderrahmane Mami Hospital
Last refreshed: 28 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04351919.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing